Does SULT2A1 variation affect DHEA sulfation and DHEA-S levels?

Dehydroepiandrosterone sulfotransferase (SULT2A1) is the primary enzyme in the adrenal zona reticularis responsible for converting DHEA into its stable sulfated reservoir, DHEA-S. Circulating levels of DHEA-S serve as a key biomarker for evaluating overall adrenal androgen reserve.

Mechanistic pathways of DHEA sulfation

• Enzymatic kinetics: In vitro studies show that SULT2A1 coding variants alter substrate affinity ($K_m$) and catalytic turnover ($V_{max}$) by disrupting enzyme dimerization or reducing immunoreactive protein levels, directly shifting sulfation efficiency.
• Gene dosage: Copy-number variations (CNVs) scale overall enzymatic capacity. For instance, individuals with two or more copies of the SULT2A1 gene excrete approximately 80% higher urinary DHEA-S than those with only a single copy.

Genotype-specific findings and adrenal reserve

• The rs2637125 variant: In genome-wide association studies, the rs2637125 GG pattern represents the common, non-risk reference genotype. It is consistently associated with relatively higher or baseline circulating DHEA-S levels.
• The minor allele association: It is the minor A allele at this locus, rather than the GG pattern, that tracks with diminished DHEA-S concentrations.
• Clinical implications: While depressed circulating DHEA-S levels reliably reflect lower adrenal androgen reserve or relative adrenal hypoandrogenism, this state does not correlate with the rs2637125 GG genotype.

Bottom line

• Although SULT2A1 variations dictate DHEA-S levels and adrenal androgen reserve, the claim is incorrect regarding the specific genotype: the rs2637125 GG pattern is associated with baseline or higher DHEA-S levels, whereas the minor A allele is the variant associated with lower hormone levels.